golimumab
Ligand Summary
Golimumab plus MTX effectively reduces the signs and symptoms of RA and is generally well tolerated in patients with an inadequate response to MTX.
ChEMBL: CHEMBL1201833
DrugCentral: 4967
LyCHI: golimumab
Target Activities
1 Activities
Items per page:
10
1 – 1 of 1
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
ANTIBODY BINDING | ||||||